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Arrhythmogenic right ventricular cardiomyopathy (ARVC) is characterized by degeneration of the
right ventricle and ventricular tachycardia originating from the right ventricle. Additionally, the dis-
ease is an inherited cardiomyopathy that mainly follows the autosomal dominant pattern. More than
10 genes have been reported as causative genes for ARVC, and more than half of ARVC patients carry
mutations in desmosome related genes. The desmosome is one of the structures involved in cell
adhesion and its disruption leads to various diseases, including a skin disease called pemphigus.
Among desmosome genes, mutations in PKP2 are most frequently identiﬁed in ARVC patients.
Although the genotype–phenotype correlations remain to be fully studied, many studies have
reported clinical manifestations of, prognosis for, and appropriate therapies for ARVC from the per-
spective of gene mutations. A collective review of these reports would enhance the understanding of
ARVC pathogenesis and clinical manifestation. This review discusses the clinical issues of ARVC from
the genetic background.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 399
2. History of desmosome genes as the cause of ARVC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 399
3. Desmosome genes for ARVC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400
3.1. PKP2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400
3.2. JUP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400
3.3. DSP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400
3.4. DSG2 and DSC2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400
4. Other causative genes for ARVC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400
4.1. ARVC1-TGFB3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 400
4.2. ARVC2-RYR2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401
4.3. ARVC4-TTN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401
4.4. ARVC5-TMEM43. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401
4.5. ARVC7-DES. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401
5. Other causative genes for ARVC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401
5.1. PLN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401
5.2. LMNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401
5.3. SCN5A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401
5.4. CTNNA3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401
6. Genotype–phenotype correlations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 402blished by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
S. Ohno / Journal of Arrhythmia 32 (2016) 398–403 3997. Progress pertaining to genetic analysis and genetic noise. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 402
8. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 402
Conﬂict of interest. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 402
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 402Fig. 1. A schematic diagram of the desmosome. Desmoglein and desmocolin
located in the transmembrane region connect with the corresponding molecules on
the neighboring cell and are linked to desmoplakin by plakophilin and plakoglobin.
Table 11. Introduction
Arrhythmogenic right ventricular cardiomyopathy (ARVC),
previously called arrhythmogenic right ventricular dysplasia
(ARVD), is an inherited disease characterized by right ventricular
degeneration and ventricular arrhythmias. ARVC is one of the
important causes of sudden cardiac deaths in young people, and
especially in young athletes [1]. The disease seems to be reported
at the end of the 19th century as “cor adipose” [2]. In 1982, Marcus
et al. ﬁrst summarized 22 cases of adult ARVC patients, including
their clinical characteristics such as male predominance, onset at
around 40 years of age, T wave inversion in precordial leads, and
ﬁbro-fatty replacement of the myocardium [3]. These clinical
characteristics are still applied in the latest diagnostic task force
criteria [4].
Familial cases of ARVC have been reported since the early
1980s. In 1985, 3 out of 5 siblings from a family were diagnosed
with ARVC, and the authors hypothesized incomplete autosomal
dominant inheritance mode with low penetrance [5]. Thus, ARVC
was suspected to be an inherited disease from the beginning, and
many physicians and researchers started to explore the genes
responsible for ARVC. Studies related to the identiﬁcation of cau-
sative genes are summarized in the next section.
The ﬁrst diagnostic criteria for ARVC published in 1994 inclu-
ded family history as one of the criteria [6]. Familial disease con-
ﬁrmed at necropsy or surgery was classiﬁed as a major criterion. A
familial history of premature sudden death (o35 years of age) due
to suspected right ventricular dysplasia or a familial history based
on clinically diagnosed disease as per the criteria were classiﬁed as
minor criteria.
To understand the pathogenesis of ARVC, many researchers
have studied the genetic background of the disease, and many
causative genes have been identiﬁed in the last decade. Among
these, the identiﬁcation of involvement of desmosomal genes in
ARVC patients was a signiﬁcant discovery [7].
Presently, genetic mutations are identiﬁed in more than 60% of
ARVC patients, and familial cascade screening is useful to diagnose
the disease before its onset in young family members.
In this review, I have described the causative genes, the char-
acteristics of the genotype, and the future perspectives for ARVC
from the viewpoint of genetics.Genotypes, gene names, and locations related to ARVC.
Genotype Gene Location Recessive form Reference
ARVC1 TGFB3 14q24.3 [24]
ARVC2 RYR2 1q43 [27]
ARVC3 Unknown 14q12-q22 [54]
ARVC4 TTN 2q32.1-q32.3 [29]
ARVC5 TMEM43 3p25.1 [33]
ARVC6 Unknown 10p14-p12 [55]
ARVC7 DES 2q35 [37]
ARVC8 DSP 6p24.3 Carvajal syndrome [10]
ARVC9 PKP2 12p11 [11]
ARVC10 DSG2 18q12.1 [12]
ARVC11 DSC2 18q12.1 [13]
ARVC12 JUP 17q21.2 Naxos disease [7]
Others PLN 6q22.1 [40]
LMNA 1q22 [41]
SCN5A 3p21 [44]
CTNNA3 10q 22.2 [45]2. History of desmosome genes as the cause of ARVC
Desmosomes are a complex formed by proteins and function to
bind the myocardial cells to each other. In the heart, desmosomes
are composed of ﬁve proteins that is, junctional plakoglobin
encoded by JUP, plakophilin-2 by PKP2, desmoplakin by DSP,
desmoglein-2 by DSG2, and desmocollin-2 by DSC2 (Fig. 1).
Desmosomes are indispensable for electrical conduction and
mechanical contraction in myocardial cells.
In 1986, the Greek cardiologist Protonotarios and his colleagues
reported cardiac abnormalities in 9 patients with familial palmo-
plantar keratosis and wooly hair [8]. All patients originated from
families on the Greek island of Naxos, and therefore the disease
was named as Naxos disease. The island of Naxos has nearly 200
unrelated families. Medical doctors and scientists in Naxos andLondon collaborated and recruited all families living on the island
of Naxos for the study. They identiﬁed 9 affected families and
performed linkage analysis for 38 members, including the 14
affected members. Using this analysis, they reported a homo-
zygous genotype on 17q21 in 1998 [9].
In 2000, a homozygous deletion mutation in JUP was ﬁnally
identiﬁed in 19 patients with Naxos disease [7].
After the discovery of JUP as a causative gene for ARVC in the
recessive form, many researchers started genetic analysis for other
desmosome genes in ARVC patients. DSP was conﬁrmed as a
causative gene in 2002 [10]. PKP2 mutations in ARVC patients
were reported in 2004 [11], while DSG2 and DSC2 mutations were
reported in 2006 [12,13].
Although most ARVC patients show the autosomal dominant
inheritance, two recessive inheritance modes have been reported
in syndromic ARVC. One of these is the Naxos disease caused by
homozygous mutations in JUP [7], and another is the Carvajal
syndrome caused by homozygous DSP mutations [14]. At ﬁrst,
Carvajal syndrome was reported as a syndromic dilated
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a homozygous mutation in DSP [14]. In 2003, another homozygous
mutation in DSP was identiﬁed in an ARVC family showing hair
and skin abnormalities [15].
Causative genes for ARVC and their respective characteristics
are summarized in Table 1.3. Desmosome genes for ARVC
3.1. PKP2
PKP2 is the most major causative gene for ARVC. PKP2 encodes
plakophilin-2, a protein with 881 amino acids with armadillo
repeat domain (Fig. 1) and has a structure similar to that of pla-
koglobin, which is encoded by JUP. In 2004, PKP2 mutations were
identiﬁed in 32 out of 120 unrelated individuals with ARVC [11].
Later studies demonstrated the low penetrance of PKP2 mutations
in ARVC [16,17]. Among the carriers of mutations in desmosome
genes, more than 70% patients in western countries carry PKP2
mutations [18]. In Asian countries, we have previously reported
the results of genetic analysis in 35 ARVC probands [19]. Among 35
probands, we identiﬁed 19 carriers with desmosome mutations,
with 10 showing mutations in PKP2 (52.6%). In China, Bao et al.
identiﬁed 57 mutation carriers from 90 ARVC patients (63.3%); of
these, 40 were PKP2 mutation carriers (70.2%) [20]. These reports
indicate that genetic screening for PKP2 in ARVC patients is
indispensable to understand their genetic backgrounds.
3.2. JUP
JUP was the ﬁrst gene identiﬁed as causative for ARVC among
the desmosome genes [7], and the structure of plakoglobin, which
is encoded by JUP, is similar to that of plakophilin (Fig. 1). How-
ever, the mutation frequency of JUP in ARVC patients is low as
compared to that of other desmosome genes. The number of JUP
mutations identiﬁed in ARVC patients is less, but plakoglobin
encoded by JUP has a remarkable effect in ARVC pathogenesis. In
an experiment where desmoplakin expression in atrial myocyte
cell lines was suppressed by siRNA, nuclear translocation of pla-
koglobin and reduction of Wnt/beta-catenin signaling were
reported [21]. In 2009, translocated plakoglobin to nuclear was
shown to bind the Tcf7l2 transcription factor, resulting in
increased expression of adipogenic factors like Wnt5b and BMP7,
which are normally inhibited by canonical Wnt signaling [22].
Therefore, JUP-encoded plakoglobin could be a key factor for dis-
solving the pathogenesis of ARVC.
3.3. DSP
DSP is the largest among the desmosome genes and encodes
the 2872 amino acid protein, desmoplakin. The N-terminus of
desmoplakin is required for localization to the desmosome and
interaction with plakophilin and plakoglobin. The C-terminus of
desmoplakin binds to the intermediate ﬁlaments (desmin) (Fig. 1).
A DSP mutation was ﬁrst identiﬁed in a homozygous manner as
the cause of Carvajal disease, which shows dilated cardiomyopathy
with wooly hair and keratoedema [14]. In 2002, a DSP mutation,
S229R, was identiﬁed in a 18 year-old male who suffered cardiac
arrest and was diagnosed with ARVC [10]. An extended clinical and
genetic analysis of his family members from 4 generation con-
ﬁrmed that the mutation was the cause of ARVC. The residue 229
located in the N-terminus of desmoplakin is involved in binding
with plakoglobin or plakophilin, and the mutation S229R would
disrupt the normal binding with those proteins.After the ﬁrst report, other DSP mutations have been identiﬁed
in ARVC patients. Although DSP is the largest among the desmo-
some genes, the number of reported mutations is small compared
to other genes. Only 12 mutations have been reported in recent
study with 439 families [18].
3.4. DSG2 and DSC2
The products of DSG2 and DSC2 are cadherin-like transmem-
brane glycoproteins that are major components of the desmosome
(Fig. 1). Mutations in both genes have been reported as the cause
of ARVC.
Mutations in DSG2 as a causative gene for ARVC were ﬁrst
reported in 2006 [12]. Among 54 ARVC probands who were
negative for mutations in DSP, PKP2, and TGFβ3, 9 heterozygous
DSG2 mutations were found.
DSC2 was the last one among the desmosome genes to be
reported as the causative gene for ARVC. Among 77 probands who
were negative for PKP2, JUP, DSP and DSG2, two frameshift
mutations that resulted in the formation of a premature termi-
nation codon in DSC2 were identiﬁed from 4 families [13].
After these reports, many mutations in DSG2 and DSC2 have
been reported. However, in European countries, the frequency of
mutations in these genes is low compare to PKP2. In a recent
report, 17 DSG2 (4%) and 5 DSC2 (1%) mutation carriers were
identiﬁed from 276 genotype positive probands [18].
In Asian countries, the frequency of DSG2 mutations is rather
higher than in Caucasians. We reported 3 DSG2 (15.8%) mutation
carriers from 19 genotype positive patients [19] and Bao et al.
reported 8 DSG2 (14%) mutation carriers from 57 patients [20].
Surprisingly, the latter reported that 3 of the 8 DSG2 mutation
carriers had homozygous mutations.
DSC2 mutations in ARVC patients are also rare in Asian coun-
tries. We identiﬁed only one DSC2 mutation carrier from 19 gen-
otype positive patients; the patient carried three DSC2 mutations;
R132C, N194K, and R203C [19]. In China, 3 DSC2 mutations were
identiﬁed from 57 patients, and two of these mutations were
identiﬁed as a single mutation [20].4. Other causative genes for ARVC
Although more than half of ARVC patients carry mutations in
desmosome genes, other genes have also been reported as causative
genes for ARVC (Table 1). In the most of these genes, their loci on
chromosomes were ﬁrst conﬁrmed by linkage analysis, and then
the speciﬁc genes were identiﬁed in the target families. Other than
desmosome genes, 7 loci have been detected in linkage analysis and
5 causative genes for ARVC have been identiﬁed. However, the
causative genes of ARVC3 in chromosome 14q12-q22 and ARVC6 in
chromosome 10q14-p12 have not been identiﬁed yet.
4.1. ARVC1-TGFB3
The ARVC1 locus on chromosome 14q23-q24 was ﬁrst identi-
ﬁed in 1994 as the causative locus for ARVC on performing linkage
analysis of two families, including a large family with 4 genera-
tions of ARVC patients [23]. However, identiﬁcation of the causa-
tive gene, TGFB3, took a lot of time. In 2005, two nucleotide sub-
stitutions in the 50UTR and 30UTR of TGFB3 were identiﬁed in
ARVC patients [24]. To conﬁrm the effect of UTR mutations in
TGFB3 gene expression, a luciferase reporter assay was performed,
and both UTR mutations were found to increase the luciferase
reporter activity. Thus, the authors explained that increased TGFB3
expression induced myocardial ﬁbrosis in accordance with pre-
vious studies [25].
S. Ohno / Journal of Arrhythmia 32 (2016) 398–403 4014.2. ARVC2-RYR2
RYR2 encodes the cardiac ryanodine receptor, which locates to
the sarcoplasmic reticulum, and is indispensable for cardiac con-
traction by controlling the calcium ions. The RYR2 mutations were
reported in various other cardiac diseases, including dilated car-
diomyopathy (DCM) and catecholaminergic polymorphic ven-
tricular tachycardia (CPVT). The locus, 1q42-q43 was conﬁrmed in
an ARVC family in 1995 [26] and the causative gene was identiﬁed
as RYR2 in 2001 [27]. The RYR2 mutation carriers in this family
showed effort-induced polymorphic ventricular tachycardia, and
there were four patients of juvenile sudden death in the family.
Post mortem examination of two subjects showed normal right
ventricular size, but large areas of fatty-ﬁbrous replacement
localized in the sub-epicardial layer of the right ventricle were
detected at the histological level [26]. In 2001, four RYR2 muta-
tions (R176Q, L433P, N2386I, and T2504M) from three ARVC
families were identiﬁed [27]. Although the affected family mem-
bers fulﬁlled the diagnostic criteria of ARVC at that time [6], this
ARVC family with RYR2 mutations might actually be a variant
of CPVT.4.3. ARVC4-TTN
ARVC4 was reported in three families with left ventricular
involvement in1997 [28], and TTN was conﬁrmed as the causative
gene for ARVC4 in 2011 [29]. TTN consists of 363 exons and
encodes the protein, titin, which is the largest protein in mam-
mals, with its name originating from the giant men in Greek
mythology. TTN mutations have been reported in other cardio-
myopathies such as hypertrophic cardiomyopathy (HCM) [30] and
dilated cardiomyopathy (DCM) [31]. ARVC4 patients with TTN
mutations displayed various phenotypes, including biventricular
dysfunction and conduction block. Therefore, overlapping pheno-
types with DCM are suspected in ARVC4 patients.
4.4. ARVC5-TMEM43
The locus of ARVC5 (chromosome 3p23) was detected in a large
ARVC family from the island of Newfoundland including more
than 200 members spanning eight generations [32]. In 2008, the
causative gene of ARVC5 was conﬁrmed as TMEM43 encoding the
transmembrane protein 43, which functions as a nuclear mem-
brane organizer [33]. The mutation identiﬁed in the large family
was S358L located in the transmembrane domain of the protein.
Mutations in TMEM43 were also identiﬁed in 2 of 41 unrelated
individuals with Emery–Dreifuss muscular dystrophy (EDMD)
[34]. As the cause of ARVC, TMEM43 mutations were regarded as
rare compared to desmosome mutations. However, recent
advances in genetic analysis have made it easy to identify TMEM43
mutations in ARVC patients. Recently, we identiﬁed double
TMEM43 mutations in a Japanese family with RV aneurysm [35].
Although ARVC patients with TMEM43 mutations fulﬁll the
ARVC task force criteria, the phenotype of ARVC due to TMEM43
mutations might be different from that due to desmosome
mutations. One of these differences includes the early onset of
ARVC. In general, ARVC onset occurs at around 30 years of age, but
in our patient with TMEM43 mutation, RV aneurysm and ven-
tricular arrhythmia were identiﬁed before birth by fetal ultrasound
[35]. In addition, the penetrance of TMEM43 related ARVC is very
high. In an analysis of 137 TMEM43 mutation carriers, all the
patients showed ARVC speciﬁc phenotype by 63 years in males
and 76 years in females [33].4.5. ARVC7-DES
The locus of ARVC7 was ﬁrst detected on chromosome 10q [36],
but in 2010, ARVC7 was determined to be caused by DES located
on chromosome 2q35 [37]. DES encodes desmin, which is one of
the types of intermediate ﬁbers in myocytes (Fig. 1) and is related
to myoﬁbrillar myopathies. The patients discussed in the ﬁrst
report of ARVC7 had myopathy and cardiomyopathy [36]. In 2010,
an ARVC7 patient without myopathy was reported [37]. The
mutation frequency of DES is not high, but in the screening of 91
ARVC probands, 2 DES mutation carriers were identiﬁed [38]. One
of the patients carried a PKP2 mutation in addition to a rare var-
iant of DES, whereas the other patient carried a frameshift DES
mutation. Therefore, the mutation frequency of DES seems to be
more than 1%.5. Other causative genes for ARVC
By using candidate gene sequence methods instead of linkage
analysis, other causative genes for ARVC have been reported.
5.1. PLN
PLN encodes phospholamban, which is indispensable for cal-
cium handling in cardiac contractions [39] and was known as the
causative gene for DCM. In 2012, van der Zwaag et al. identiﬁed
PLN-R14del in 12 out of 97 ARVC and 39 out of 257 DCM patients
in the Netherlands [40]. However, no PLN mutations except for
R14del have been reported in ARVC patients.
5.2. LMNA
LMNA encodes lamin A/C, which functions in the lining of the
nuclear membrane and is indispensable for stabilization of cells.
LMNA mutations were reported in various systemic diseases,
including Emery–Dreifuss muscle dystrophy and premature aging
syndrome. In the cardiovascular ﬁeld, LMNA mutations were
identiﬁed in DCM patients, especially those with sinus bradycardia
and conduction disturbance. In 2011, four LMNA mutations in
ARVC patients were reported [41]. Two of the four patients died
suddenly at ages 54 and 67, and one died from severe heart failure
at the age of 48 years. The histological characteristics of one of the
patients were compatible with those of ARVC, including ﬁbro-fatty
replacement. Recently, we reported two ARVC families with LMNA
mutations [42]. ARVC probands in both families showed brady-
cardia and were implanted with pacemakers.
5.3. SCN5A
SCN5A encodes the cardiac sodium channel, and mutations in
SCN5A cause various cardiac diseases, including long QT syndrome
type 3, Brugada syndrome, progressive cardiac conduction disease,
and DCM [43]. In 2008, an ARVC patient with a SCN5A splice
variant, c.3840þ1g4a, was reported, and frequent VT was
recorded in his ICD [44].
5.4. CTNNA3
CTNNA3 is the newest candidate gene for ARVC [45]. Alpha-T-
catenin encoded by CTNNA3 binds with plakophilins and functions
in the cell–cell adhesion in cardiomyocytes. Two CTNNA3 muta-
tions, c.281t4a (p.V94D) and c.2293_2295delTTG (p.dl765L) were
identiﬁed in 2 out of 76 ARVC patients without any mutations in
desmosome genes. In functional analysis, CTNNA3-V94D showed
disabled interaction with β-catenin, and CTNNA3-del765L showed
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suggest a causal relationship between CTNNA3 mutations and
ARVC pathology.6. Genotype–phenotype correlations
In certain genetic diseases with multiple genotypes, genotype–
phenotype correlations are well studied and used for diagnosis
and treatment. For example in long QT syndrome, phenotypes
predict the genotypes, and genotyping is useful to predict prog-
nosis of the patients and to decide treatment. However, in ARVC,
genotype–phenotype correlations have not been fully examined as
of yet. One of the reasons being that most of the mutations are
identiﬁed in PKP2 [18]. Another reason for the lack of study is the
low penetrance of the mutations [17].
Recently, a study that analyzed the phenotypes and gene
mutations related to ARVC was reported. In the probands, muta-
tion positive status did not affect clinical characteristics and out-
comes. In contrast, family members with mutations were more
likely to meet Task Force Criteria for ARVC [4] (40% vs 18%),
experience sustained ventricular arrhythmias (11% vs 1%), and die
from a cardiac cause (2% vs 0%) than family members without
mutations [18]. Among 116 desmosome gene mutation carriers in
another study, the event rate was higher among patients with
deﬁnite ARVC than among borderline or phenotype negative
patients [46].
Correlations between mutation type and phenotype have been
reported. We compared the disease onset of probands with 12
missense and 7 non-missense mutation carriers. All non-missense
mutations were found in PKP2 [19]. In our study, the disease
onsets were signiﬁcantly younger in the patients with non-
missense mutations than in those with missense mutations
(29.4712.4 vs 45.8714.2 years, P¼0.027). In contrast, Alcalde
et al. reported that the disease onsets in patients with stop gain
mutations were later than those in patients with missense muta-
tions (27 vs 39 years old, Po0.05). Although, it is difﬁcult to clarify
the reason of the discrepancy, the deﬁnition of onset was different
between studies. It would be difﬁcult to deﬁne disease onsets in
the patients whose ﬁrst symptoms were ventricular arrhythmias,
because cardiologists would never recognize that the patients
experienced ventricular tachycardia if the patients did not com-
plain of their symptoms or had syncope.7. Progress pertaining to genetic analysis and genetic noise
At present, the causative genes for ARVC are known, and we
can screen all the genes in patients who are diagnosed with ARVC.
The gold standard of sequencing for genetic screening is the
Sanger method, which needs two times of PCR for target exons. All
the target exons can be screened in genes related to ARVC. How-
ever, Sanger methods need a long time and are expensive if we
screen all the exons in those genes. The total number of exons in
desmosome genes is nearly 90. In addition, TTN, a causative gene
for ARVC4, has 363 exons, and RYR2, a causative gene for ARVC2,
has 105 exons. The screening of all ARVC-related genes by Sanger
methods therefore seems to be a difﬁcult task.
However, we can now approach the new sequencing methods,
next generation sequencing (NGS) methods [47]. These methods
are useful not only for whole genome or exome sequencing but
also for target gene sequencing [48]. Especially for cardiomyo-
pathies, multiple panels for genetic analysis are available on the
market. If these panels are used, mutations in ARVC patients can
easily be detected in a week.In the NGS era, many rare variants can be detected in genetic
analysis, some of which are related with the disease. Therefore, the
true mutation(s) causative for the disease need to be distinguished
from other genetic noise. In 2011, Kapplinger et al. reported
background genetic noise in ARVC [49]. They performed a genetic
analysis of PKP2, DSP, DSG2, DSC2, and TMEM43 for 92 probands
diagnosed with ARVC and 427 controls. Radical mutations result-
ing in stop codons were identiﬁed in 43% of probands and in 0.5%
of controls. In contrast, missense mutations were identiﬁed in 21%
of the probands and 16% of controls; thus, the frequency of mis-
sense mutations was similar between probands and controls. They
further analyzed the ARVC related genes and locations of missense
mutations that were highly detected in controls and found that
missense mutations in DSP and DSG2, especially at the C-terminals
of both genes, were highly detected in controls [49]. To avoid
misunderstanding of the detected variants in the ARVC related
genes, a comparison of the detected mutations with data for
ethnically matched controls is needed, for example, the 1000
genome study [50] and the ExAC Browser (http://exac.broad-
institute.org/).
In silico prediction software, SIFT [51], PolyPhen2 [52], CADD
[53], and other prediction systems are useful to evaluate a speciﬁc
mutation which is detected in a patient. However, even if the in
silico software predicts a mutation as pathogenic, we need to
examine whether the genetic result is compatible with the
phenotype.8. Conclusion
In the last decade, there has been remarkable progress in
determining the genetic background of ARVC and new technolo-
gies for genetic analysis have been developed. The next step is to
utilize this genetic progress for the treatment of ARVC, including
the prevention of sudden cardiac death in young people.Conﬂict of interest
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